<div id="readability-page-1"><p>Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 560,264 shares,  a drop of 85.9% from the November 30th total of 3,977,435 shares. Based on an average daily trading volume, of 139,822 shares, the days-to-cover ratio is presently 4.0 days. Approximately 7.0% of the shares of the company are sold short. Approximately 7.0% of the shares of the company are sold short. Based on an average daily trading volume, of 139,822 shares, the days-to-cover ratio is presently 4.0 days.</p><div><p><span></span><span>Get <strong>Sutro Biopharma</strong> alerts:</span></p></div><h2>Sutro Biopharma Price Performance</h2><p>Shares of STRO traded up $0.25 on Wednesday, hitting $10.63. The company's stock had a trading volume of 40,237 shares, compared to its average volume of 116,353. The company has a 50 day moving average price of $9.48 and a 200 day moving average price of $8.79. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $21.50. The company has a market capitalization of $90.42 million, a PE ratio of -0.41 and a beta of 1.61. </p><p>Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.25). The business had revenue of $9.69 million during the quarter, compared to the consensus estimate of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%.  On average, equities analysts forecast that  Sutro Biopharma will post -2.92 EPS for the current year. </p><h2>Insider Transactions at Sutro Biopharma</h2><p>In other news, Director Connie Matsui bought 5,000 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director directly owned 5,000 shares of the company's stock, valued at $40,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 11,175 shares of company stock valued at $89,598. Company insiders own  5.90% of the company's stock. </p><h2>Hedge Funds Weigh In On Sutro Biopharma</h2><p>A number of institutional investors have recently modified their holdings of STRO. Catalyst Funds Management Pty Ltd acquired a new position in shares of  Sutro Biopharma during the second quarter worth approximately $27,000.  Savant Capital LLC bought a new stake in shares of  Sutro Biopharma during the second quarter worth approximately $37,000.  Bridgeway Capital Management LLC lifted its holdings in  Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock valued at $37,000 after buying an additional 30,000 shares during the period.  CWM LLC lifted its holdings in  Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company's stock valued at $40,000 after buying an additional 23,941 shares during the period.  Finally, Vanguard Personalized Indexing Management LLC boosted its stake in  Sutro Biopharma by 174.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company's stock valued at $43,000 after acquiring an additional 38,561 shares during the last quarter. 96.99% of the stock is owned by institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts recently issued reports on STRO shares. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Sutro Biopharma in a research report on Monday. Wedbush  restated a &#34;neutral&#34; rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft  reaffirmed a &#34;buy&#34; rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Sutro Biopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Finally, HC Wainwright lifted their target price on Sutro Biopharma to $10.00 and gave the stock a &#34;neutral&#34; rating in a research report on Monday. Two analysts have rated the stock with a Buy rating, four have issued  a Hold rating and two have issued  a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $33.60.</p><p><b>Get Our Latest Report on STRO</b></p><h2>Sutro Biopharma Company Profile</h2> (Get Free Report)<p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.  </p><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Sutro Biopharma</li><li>How Long Will $1M Last in Retirement?</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Washington prepares for war</li><li>GOLD ALERT</li><li>Punch these codes into your ordinary brokerage account</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2><p>Before you consider Sutro Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p><p>While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

STRO

<p>Sutro Biopharma, Inc. (NASDAQ:STRO) experienced an 85.9% drop in short interest in December, with shares totaling 560,264 as of December 15th. The short-interest ratio is 4.0 days based on an average daily volume of 139,822 shares. The stock price increased by $0.25 to $10.63, with a trading volume of 40,237 shares. Analysts have mixed ratings, with some upgrading and others downgrading the stock.</p>

Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 85.9% in December